Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

Neoplasms Clinical Trial

— ONCO DVT  

Official title:

Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03895502
• Other study ID #: Y0019
• Status: Completed
• Phase: Phase 4
• Start date: May 27, 2019
• Est. completion date: August 31, 2023

Study information

• Verified date: October 2023
• Source: Kyoto University, Graduate School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein thrombosis.

Description:

Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), is a major health problem in the world. There have been many clinical studies evaluating PE and/or proximal DVT, although data on isolated distal DVT (IDDVT) has been quite limited. However, IDDVT was reported to account for about half of all the diagnoses of DVT detected on ultrasound in daily clinical practice, and optimal management strategies for these patients are becoming clinically more relevant. The current American College of Chest Physicians (ACCP) guidelines suggest the same approach for IDDVT patients with cancer as proximal DVT patients with cancer. However, whether anticoagulation therapy should be continued indefinitely remains uncertain and the duration of treatment in these patients might vary widely in daily clinical practice. Recently, some observational studies reported that IDDVT patients with cancer have a high risk of VTE recurrence, suggesting the benefit of prolonged anticoagulation therapy. In this open-label, superiority trial, we will randomly assign IDDVT patients with active cancer to receive either edoxaban for 3 months (short DOAC group) or edoxaban for 12 months (long DOAC group).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 605
• Est. completion date: August 31, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Patients with newly found isolated distal deep vein thrombosis

• Patients complicated with active cancer

• Patients who are scheduled to be treated by anticoagulation therapy.

Exclusion Criteria:

• Patients with anticoagulation therapy for the index event before 10 days of allocation.

• Patient under anticoagulation therapy for the purpose of other than the index event.

• Patients with thrombolysis therapy or IVC filter at the Index event.

• Patients with creatinine clearance less than 30 ml/min.

• Patients who are expected to have a life prognosis of 3 months or less.

• Patients with pulmonary embolism.

• Patients who are not appropriate for the participation of the study.

Related Conditions & MeSH terms

• Anticoagulant
• Neoplasms
• Thrombosis
• Venous Thrombosis

Intervention

Drug:
• 12-month Edoxaban
Prescription of Edoxaban for 12 months
• 3-month Edoxaban
Prescription of Edoxaban for 3 months

Locations

Country	Name	City	State
Japan	Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine	Kyoto

Sponsors (1)

Lead Sponsor	Collaborator
Takeshi Morimoto

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Symptomatic VTE recurrence event or VTE related death event	Symptomatic VTE recurrence event is defined as PE and/or DVT with symptoms accompanied by confirmation of new thrombus or exacerbation of the thrombus by objective imaging examinations or autopsy. VTE related death event is defined as death due to a documented PE (either an objective test prior to death of the subject or PE detected during autopsy) or unexplained death (i.e. death without a clear alternate cause and not a primary consequence of subject's underlying cancer.)	12 months
Secondary	Major bleeding event (ISTH criteria)	Major bleeding is defined as International Society of Thrombosis and Hemostasis (ISTH) major bleeding, which consisted of a reduction in the hemoglobin level by at least 2 g/dL, transfusion of at least 2 units of blood or symptomatic bleeding in a critical area or organ.	12 months
Secondary	All-cause death		12 months
Secondary	Symptomatic VTE recurrence event	Symptomatic VTE recurrence event is defined as PE and/or DVT with symptoms accompanied by confirmation of new thrombus or exacerbation of the thrombus by objective imaging examinations or autopsy.	12 months
Secondary	VTE related death event	VTE related death event is defined as death due to a documented PE (either an objective test prior to death of the subject or PE detected during autopsy) or unexplained death (i.e. death without a clear alternate cause and not a primary consequence of subject's underlying cancer.)	12 months
Secondary	Clinically relevant non-major (CRNM) bleeding	A bleeding event will be classified as a clinically relevant non-major bleeding event if it is overt (i.e. is symptomatic or visualized by examination) not meeting the criteria for major bleeding, requires medical attention or is associated with discomfort for the subject such as pain, or impairment of activities of daily life.	12 months
Secondary	Clinically relevant bleeding	Clinically relevant bleeding is defined as major or CRNM bleeding.	12 months
Secondary	Bleeding related death event	Bleeding related death event is defined as a bleeding event directly led to death. Examples of fatal bleeding events are an intracranial hemorrhage that led to herniation of the brain and death within 24 hours, and a massive gastrointestinal hemorrhage that results in shock, hemodynamic collapse, and death.	12 months
Secondary	Unsuspected recurrent DVT by follow-up ultrasound examinations	Unsuspected DVT by follow-up ultrasound examinations is a thrombus that is detected during follow-up ultrasound testing without suspicion of DVT.	12 months
Secondary	Unsuspected recurrent VTE by any imaging examinations	Unsuspected recurrent VTE is defined as thrombi that are detected during imaging testing performed for other reasons (e.g., computed tomography (CT) for cancer staging) and not for suspicion of DVT or PE.	12 months
Secondary	Change of serum D-dimer levels during follow-up period		12 months
Secondary	Any adverse outcomes during invasive procedures	Adverse outcomes include bleeding events, recurrent VTE events, all-cause deaths.	12 months